The Short Answer
Elevated circulating LDL-C (>= 130 mg/dL) or Apolipoprotein B (ApoB >= 90 mg/dL) particles that gradually deposit plaque inside coronary and carotid arteries. First-line low-to-moderate dose statins (Atorvastatin 10-20 mg or Rosuvastatin 5-10 mg), soluble fiber, and Ezetimibe lower LDL-C by 38% to 55% within 4-6 weeks. Under the surface, Reduced hepatic LDL-receptor recycling or excess hepatic VLDL assembly prolongs plasma residence of ApoB100 particles, enabling transcytosis across arterial endothelium, oxidative modification, and macrophage foam-cell formation. [1][2].
Hearing or reading "High Cholesterol, Elevated LDL-C & ApoB (Dyslipidemia)" (coded in medical charts as ICD-10-CM E78.5, and also known as High Cholesterol, Hypercholesterolemia, Elevated LDL Cholesterol, Elevated Apolipoprotein B (ApoB)) can feel intimidating when a clinician only has 7 minutes to explain it. In plain kitchen-table terms, Elevated circulating LDL-C (>= 130 mg/dL) or Apolipoprotein B (ApoB >= 90 mg/dL) particles that gradually deposit plaque inside coronary and carotid arteries. First-line low-to-moderate dose statins (Atorvastatin 10-20 mg or Rosuvastatin 5-10 mg), soluble fiber, and Ezetimibe lower LDL-C by 38% to 55% within 4-6 weeks. [1].
Physiologically, Reduced hepatic LDL-receptor recycling or excess hepatic VLDL assembly prolongs plasma residence of ApoB100 particles, enabling transcytosis across arterial endothelium, oxidative modification, and macrophage foam-cell formation. [2]. Understanding that root mechanism takes the mystery out of your diagnosis and shows you exactly why targeted daily steps and evidence-based treatments work [2][3].